The Rothman Institute of Orthopedics at Thomas Jefferson University Hospital, 925 Chestnut Street, 2nd Floor, Philadelphia, PA 19107, USA.
J Bone Joint Surg Am. 2013 Sep 4;95(17):1606-11. doi: 10.2106/JBJS.L.00882.
More than 3 million people in the United States have atrial fibrillation, most of whom are being managed with anticoagulation therapy for life. The goal of the present study was to examine the effect of chronic anticoagulation therapy on patients with atrial fibrillation who undergo total joint arthroplasty.
We retrospectively reviewed all patients undergoing aseptic primary or revision total joint arthroplasty at our facility from March 2007 to August 2011. One hundred and sixty-one patients with atrial fibrillation (Group A) were compared with 161 matched controls (Group B). A total of 112 hips and 210 knees underwent 239 primary arthroplasties and eighty-three revisions. The groups were compared with use of conditional logistic regression (with matching on the basis of the involved joint [hip or knee], type of procedure [revision or primary], age, and sex) with regard to the length of hospital stay, postoperative hemoglobin levels, transfusion requirements, and readmissions.
The preoperative length of stay (1.7 versus 0.2 days; p < 0.0001), postoperative length of stay (4.6 versus 3.2 days; p = 0.0002), and total length of stay (6.3 versus 3.4 days; p < 0.0001) were significantly longer for patients with atrial fibrillation (Group A). Hemoglobin levels were lower (but not significantly so) for Group A at baseline (13.1 versus 13.8 mg/dL), on Postoperative Day 2 (10.1 versus 10.6 mg/dL), on Postoperative Day 3 (9.8 versus 10.2 mg/dL), on Postoperative Day 4 (9.6 versus 10.1 mg/dL), on Postoperative Day 5 (9.7 versus 9.9 mg/dL), and at discharge (9.9 versus 10.3 mg/dL). Group A had a significantly higher prevalence of blood transfusion (15.5% versus 3.7%; p = 0.0005) and periprosthetic joint infection (5.6% versus 0.62%; p = 0.0196). A diagnosis of atrial fibrillation (odds ratio, 4.09; 95% confidence interval, 2.05 to 8.18; p < 0.0001) significantly increased the odds of total joint arthroplasty complication and the need for hospital readmission.
Patients with preoperative atrial fibrillation undergoing total joint arthroplasty had an increased length of hospital stay, increased transfusion requirements, and an increased risk of periprosthetic joint infection and unplanned hospital readmission.
美国有超过 300 万人患有心房颤动,其中大多数人需要终身接受抗凝治疗。本研究的目的是探讨慢性抗凝治疗对接受全关节置换术的心房颤动患者的影响。
我们回顾性分析了 2007 年 3 月至 2011 年 8 月在我院接受无菌初次或翻修全关节置换术的所有患者。将 161 例心房颤动患者(A 组)与 161 例匹配对照组(B 组)进行比较。共有 112 髋和 210 膝接受了 239 例初次关节置换术和 83 例翻修术。使用条件逻辑回归(基于受累关节[髋或膝]、手术类型[翻修或初次]、年龄和性别进行匹配)比较两组患者的住院时间、术后血红蛋白水平、输血需求和再入院情况。
心房颤动患者(A 组)的术前住院时间(1.7 天 vs. 0.2 天;p < 0.0001)、术后住院时间(4.6 天 vs. 3.2 天;p = 0.0002)和总住院时间(6.3 天 vs. 3.4 天;p < 0.0001)明显更长。A 组基线时(13.1 毫克/分升 vs. 13.8 毫克/分升)、术后第 2 天(10.1 毫克/分升 vs. 10.6 毫克/分升)、术后第 3 天(9.8 毫克/分升 vs. 10.2 毫克/分升)、术后第 4 天(9.6 毫克/分升 vs. 10.1 毫克/分升)、术后第 5 天(9.7 毫克/分升 vs. 9.9 毫克/分升)和出院时(9.9 毫克/分升 vs. 10.3 毫克/分升)的血红蛋白水平较低(但无统计学意义)。A 组输血(15.5% vs. 3.7%;p = 0.0005)和假体周围关节感染(5.6% vs. 0.62%;p = 0.0196)的发生率明显更高。心房颤动的诊断(比值比,4.09;95%置信区间,2.05 至 8.18;p < 0.0001)显著增加了全关节置换术并发症和需要住院再入院的几率。
术前患有心房颤动的接受全关节置换术的患者住院时间延长、输血需求增加,并且假体周围关节感染和计划外住院再入院的风险增加。